AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

IMT in Asthma: Activity, Coping, Self-Management

Recruitingn/aAges 18 Years - 65 YearsAllIstanbul Esenyurt University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The aim of this study is to investigate asthma patients' experiences with an 8 week IMT and the perceived effects of this intervention on physical activity, coping strategies, and asthma self-management. A qualitative methodological design will be applied to understand the experiences of patients participating in the IMT program, how the program affected their daily activities, how they coped with symptoms and difficulties, and how they managed their condition.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Being between the ages of 18-65 * Having been diagnosed with severe persistent, non-allergic asthma by a pulmonologist in accordance with the Global Initiative for Asthma (GINA) guideline criteria, * Patients with type 2 inflammation markers. According to accepted standards; peripheral eosinophils \<150/ยตL and/or negative skin prick test and/or total IgE \<30 kU/L * Bronchodilator response (\>12% or 200 mL improvement in FEV1% predicted following inhalation of 400 mg salbutamol) * Diagnosis-follow-up period: Patients diagnosed at least 6 months prior, under follow-up and treatment, and/or with controlled asthma * Having completed the pulmonary rehabilitation program * Completion of 8 weeks of inspiratory muscle training (IMT) * Patients who have read, understood, and signed the informed consent form Exclusion Criteria: * Having recently had a respiratory tract infection recently (within the last month), * Having a smoking history of more than 10 pack-years or having a history of smoking within 6 months after quitting smoking * Having received oral corticosteroid treatment in the last 4 weeks, * Having a Body Mass Index \>35, * Eosinophilic Granulomatosis Polyangiitis (EGPA) and Allergic Bronchopulmonary Aspergillosis (ABPA), * Vasculitis, * History of malignancy, * Pregnancy, * Previous lung surgery, use of long-term oxygen therapy * Having accompanying restrictive lung diseases (advanced kyphoscoliosis, ankylosing spondylitis) and neuromuscular diseases (myastania gravis, muscular dystrophies, myopathies) that will prevent healthy respiratory function testing and rehabilitation. * Cognitive dysfunction, mental retardation, dementia, or other conditions that make it difficult to follow the protocol, * Unwillingness to continue participating in the study, * Communication difficulties or intellectual deficiencies
๐Ÿ’Š

What it tests

  • other
๐Ÿ“

Where

1 site
Istanbul Esenyurt University
Istanbul, Turkey (Tรผrkiye)
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy